Soligenix's upcoming catalysts highlight growth potential as it sheds light on its commercialization of sgx301

New york, new york--(newsfile corp. - february 9, 2021) - pcg digital: soligenix (nasdaq: sngx) continues to build excitement for its sgx301 candidate following strong phase 3 data and commercialization plans. the company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking sgx301 candidate for the treatment of cutaneous t-cell lymphoma (ctcl). here are some key takeaways from the commercialization q&a: 1. soligenix will commercialize sgx301 in the u.s....
SNGX Ratings Summary
SNGX Quant Ranking